Alzheimer Disease Clinical Trial
Official title:
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Biomarker and Safety Study of PTI-125 in Mild-to-moderate Alzheimer's Disease Patients
Verified date | September 2021 |
Source | Cassava Sciences, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
Status | Completed |
Enrollment | 64 |
Est. completion date | March 31, 2020 |
Est. primary completion date | March 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 85 Years |
Eligibility | Inclusion Criteria: - Ages >= 50 and <= 85 years - Informed consent form (ICF) signed by the subject or legally acceptable representative. - Clinical diagnosis of dementia due to possible or probable Alzheimer's disease - Mini-Mental State Examination score >= 16 and <= 26 at screening - If female, postmenopausal for at least 1 year - Patient living at home, senior residential setting, or an institutional setting without the need for continuous (i.e. 24-h) nursing care - General health status acceptable for participation in the study - Fluency (oral and written) in English or Spanish - If receiving memantine, rivastigmine, galantamine or an AChEI, receiving a stable dose for at least 3 months. If receiving donepezil, any dose lower than 23 mg once daily. - The patient is a non-smoker for at least 3 years. - The patient or legal representative must agree to comply with the drawing of blood samples and with a lumbar puncture and the drawing of cerebrospinal fluid samples. - The patient has a ratio of total tau/Aß42 in cerebrospinal fluid >= 0.28. - Patient has a caregiver or legal representative responsible for administering the drug and recording the time. Exclusion Criteria: - Exposure to an experimental drug, experimental biologic or experimental medical device within the longer of 5 half-lives or 3 months before screening - Enrollment in the previous PTI-125 trial - A medical condition that would interfere with a lumbar puncture - Residence in a skilled nursing facility and requiring 24 h care. - Clinically significant laboratory test results - Clinically significant untreated hypothyroidism - Insufficiently controlled diabetes mellitus - Renal insufficiency (serum creatinine > ULN) - Malignant tumor within 3 years before screening (except squamous and basal cell carcinoma or cervical carcinoma in situ or localized prostate cancer or localized stage 1 bladder cancer) - History of ischemic colitis or ischemic enterocolitis - Unstable medical condition that is clinically significant in the judgment of the investigator - Alanine transaminase (ALT) or aspartate transaminase (AST) > ULN or total bilirubin > ULN. - History of myocardial infarction or unstable angina within 6 months before screening - History of more than 1 myocardial infarction within 5 years before screening - Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (patients with a pacemaker are acceptable) - Symptomatic hypotension, or uncontrolled hypertension - Clinically significant abnormality on screening electrocardiogram (ECG), including but not necessarily limited to a confirmed corrected QT interval value >= 450 msec for males or >= 470 msec for females. - Stroke within 18 months before screening, or history of a stroke concomitant with onset of dementia - History of brain tumor or other clinically significant space-occupying lesion on CT or MRI - Head trauma with clinically significant loss of consciousness within 12 months before screening or concurrent with the onset of dementia - Onset of dementia secondary to cardiac arrest, surgery with general anesthesia, or resuscitation - Specific degenerative Central Nervous System disease diagnosis other than Alzheimer's disease (eg, Huntington's disease, Creutzfeld-Jacob disease, Down's syndrome, Frontotemporal Dementia, Parkinson's disease) - Wernicke's encephalopathy - Active acute or chronic Central Nervous System infection - Donepezil 23 mg quaque die currently or within 3 months prior to randomization - Discontinued AChEI < 30 days prior to randomization - Antipsychotics; low doses are allowed only if the subject has received a stable dose for at least 3 months before randomization - Tricyclic antidepressants and monoamine oxidase inhibitors - Anxiolytics or sedative-hypnotics, including barbiturates (unless given in low doses for benign tremor); low doses of benzodiazepines and zolpidem are allowed - Immunosuppressants, including systemic corticosteroids, if taken in clinically immunosuppressive doses (Steroid use for allergy or other inflammation is permitted.) - Antiepileptic medications if taken for control of seizures - Chronic intake of opioid-containing analgesics - Sedating H1 antihistamines - Nicotine therapy (all dosage forms including a patch), varenicline (Chantix), or similar therapeutic agent within 30 days before screening - Clinically significant illness within 30 days of enrollment - History of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease - Positive serum hepatitis B surface antigen (HBsAg) or positive hepatitis C virus HCV antibody test at screening - Positive HIV test at screening - Positive urine drug test at screening - Loss of a significant volume of blood (> 450 mL) within 4 weeks prior to the study - Suicidality on C-SSRS at screening |
Country | Name | City | State |
---|---|---|---|
United States | Cognitive Clinical Trials | Bellevue | Nebraska |
United States | Cognitive Clinical Trials | Gilbert | Arizona |
United States | Centex Studies, Inc. | Houston | Texas |
United States | Centex Studies, Inc. | McAllen | Texas |
United States | Optimus U | Miami | Florida |
United States | Cognitive Clinical Trials | Omaha | Nebraska |
United States | IMIC, Inc. | Palmetto Bay | Florida |
United States | Cognitive Clinical Trials | Surprise | Arizona |
United States | Advanced Memory Research Institute | Toms River | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Cassava Sciences, Inc. | National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Target Engagement Assays: Change From Baseline in Filamin A (FLNA) Linkages to alpha7 Nicotinic Acetylcholine Receptor (alpha7nAChR) and Toll-like Receptor 4 (TLR4) in Subject Lymphocytes | FLNA linkages to these two receptors were assessed by densitometric quantitation of immunoblot bands of each receptor (detected by a specific antibody) in anti-FLNA precipitates. The measure is noted as a ratio to total FLNA. | Day 1 to Day 28 | |
Other | Plasma P-tau181 | Percent change in plasma P-tau181 | Day 1 to Day 28 | |
Other | Percent Change From Baseline in SavaDx, a Novel Plasma Biomarker | SavaDx is a novel plasma biomarker | Day 1 to Day 28 | |
Primary | Change From Baseline in CSF Abeta42 | Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid levels of Amyloid beta42 | Screening to Day 28 | |
Primary | Change From Baseline in CSF Total Tau. | Change from Baseline (screening sample) to Day 28 in cerebrospinal fluid total tau. | Screening to Day 28 | |
Primary | Change From Baseline in CSF P-tau181 | Change from Baseline (screening) to Day 28 in cerebrospinal fluid P-tau181 | Screening to Day 28 | |
Primary | Change From Baseline in CSF Neurogranin | Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurogranin | Screening to Day 28 | |
Primary | Change From Baseline in CSF Neurofilament Light Chain | Change from Baseline (screening) to Day 28 in cerebrospinal fluid neurofilament light chain | Screening to Day 28 | |
Primary | Change From Baseline in CSF YKL-40 | Change from Baseline (screening) in cerebrospinal fluid YKL-40 | Screening to Day 28 | |
Secondary | Paired Associates Learning Test | Cognitive test assessing episodic memory. Boxes are displayed on the screen and are "opened" in a randomized order. One or more of them contains a pattern. The patterns are then displayed in the middle of the screen, one at a time and the participant must select the box in which the pattern was originally located. If the participant makes an error, the boxes are opened in sequence again to remind the participant of the locations of the patterns. The number of boxes increases progressively to a total of 8. | Day 1 to Day 28 | |
Secondary | Spatial Working Memory Test | Cognitive assessment of spatial working memory: A number of colored squares (boxes) are shown on the screen. By selecting the boxes and using a process of elimination, the subject should find one yellow 'token' in each of a number of boxes and use them to fill up an empty column on the right-hand side of the screen. The number of boxes is gradually increased to a total of 8 for the subjects to search. The colors and positions of the boxes are changed from trial to trial to discourage stereotyped search strategies. | Day 1 to Day 28 | |
Secondary | CSF IL-6, sTREM2, HMGB1, Albumin, IgG | Change from Baseline (screening sample) to Day 28 in secondary CSF biomarkers of neuroinflammation and blood-brain barrier integrity | Screening to Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A | |
Withdrawn |
NCT02707978 -
F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)
|
Phase 2 |